In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity.
Theodoros EleftheriadisGeorgios PissasMaria SounidakiGeorgia AntoniadiNikolaos AntoniadisVassilios LiakopoulosIoannis StefanidisPublished in: International urology and nephrology (2017)
In human cell cultures, everolimus is inferior to tacrolimus in inhibiting cellular alloimmunity, but equally effective as regards humoral alloimmunity. Thus, everolimus might be a safe alternative in case of tacrolimus toxicity, particularly after the early period of kidney transplantation.